Tamsulosin Hydrochloride Capsule
Product Images NDC 68788-7050

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68788-7050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over time following single-dose administration of 0.4 mg capsules under fasted and fed conditions in 8 subjects. The x-axis represents time in hours up to 36 hours, and the y-axis shows plasma concentration in ng/mL up to 25 ng/mL. The graph compares concentration trends between fasted and fed states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean symptom score changes over treatment duration in weeks. Three treatments are compared: 0.8 mg, 0.4 mg, and placebo. The y-axis represents mean change, and the x-axis shows treatment duration from 0 to 13 weeks plus LOCF. The 0.8 mg treatment shows the greatest symptom score reduction, followed by 0.4 mg, with placebo showing the least change.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph depicting the mean change from baseline in total AUA symptom score over a 13-week treatment duration. The x-axis represents weeks of treatment, and the y-axis shows mean change. Three treatment groups are shown: 0.8 mg, 0.4 mg, and placebo, each represented by different symbols and lines. Mean symptom scores decrease over time for all groups, with treatment groups showing a greater reduction than placebo by week 13.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec over treatment duration in weeks. It compares three groups: 0.8 mg dose, 0.4 mg dose, and placebo, with different symbols for each. The x-axis represents treatment duration in weeks, and the y-axis shows mean change in peak urine flow rate.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

Line graph showing the mean increase in peak urine flow rate (mL/sec) over treatment duration in weeks for Study 2. The graph compares three treatment groups: 0.8 mg, 0.4 mg, and placebo, indicating changes in flow rate across multiple time points up to 13 weeks and LOCF.*

FDA Label Image

Tamsulosin Hydrochloride Capsules Usp 04mg (Tamsulosin Fig6)

Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg by Preferred Pharmaceuticals, Inc. The label states it is generic for Flomax, manufactured by Aurobindo Pharma Limited. It includes storage instructions, warnings, and dosage directions in English and Spanish. The design features yellow and white panels with text and a barcode.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular components and arrangement, including aromatic rings, functional groups, and the hydrochloride (HCl) salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.